Treatment of pediatric febrile neutropenia in the era of vancomycin-resistant microbes

Pediatric Blood and Cancer

Volumn 44, Issue 3, 2005, Pages 207-214

  Kline, Ronald M ^a,c   Baorto, Elizabeth P ^b  

^a Children's Ctr Cancer Blood Dis   (United States)

^b Atlantic Health   (United States)

^c Pediat Div Compreh Cancer C   (United States)

Author keywords

Fever; Neutropenia; Survey; Vancomycin resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; CONTROLLED STUDY; E-MAIL; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; STAPHYLOCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CHILD; HUMANS; NEOPLASMS; NEUTROPENIA; QUESTIONNAIRES; STAPHYLOCOCCUS; VANCOMYCIN RESISTANCE;

EID: 13444278485     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20224     Document Type: Article

References (52)

1. Rodriguez V, Burgess M, Bodey GP. Management of fever of unknown origin in patients with neoplasms and neutropenia. Cancer 1973;32:1007-1012.
2. Tattersall MH, Hutchinson RM, Gaya H, et al. Empirical antibiotic therapy in febrile patients with neutropenia and malignant disease. Eur J Cancer 1973;9:417-423.
3. Tattersall MH, Spiers AS, Darrell JH. Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropenia. Lancet 1972;1:162-165.
4. Nachman JB, Honig GR. Fever and neutropenia in children with neoplastic disease: An analysis of 158 episodes. Cancer 1980;45: 407-412.
5. Bodey GP, Rodriguez V, Chang HY, et al. Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer 1978;41:1610-1622.
6. Bishop JF, McLennan R, Whiteside MG. The management of febrile episodes in neutropenic cancer. Med J Aust 1977;1:473-475.
7. Wischnewski N, Kampf G, Gastmeier P, et al. Prevalence of primary bloodstream infections in representative German hospitals and their association with central and peripheral vascular catheters. Zentralbl Bakteriol 1998;287:93-103.
8. Karthaus M, Doellmann T, Klimasch T, et al. Central venous catheter infections in patients with acute leukemia. Chemotherapy 2002;48:154-157.
9. Karthaus M, Carratala J. Changes in the epidemiology of infections in patients with febrile neutropenia. Wien Med Wochenschr 2001; 151:47-52.
10. Gamis AS, Howells WB, DeSwarte-Wallace J, et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: A report from the Children's Cancer Group Study CCG-2891. J Clin Oncol 2000;18:1845-1855.
11. Lex C, Korholz D, Kohlmuller B, et al. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma - A rationale for tailored supportive care. Support Care Cancer 2001; 514-521.
12. Muller J, Kovacs G, Schmidt M, et al. Frequent infections of neutropenic pediatric patients and therapeutic modalities. Magy Onkol 2000;44:289-295.
13. Blijlevens NM, Donnelly JP, de Pauw BE. Empirical therapy of febrile neutropenic patients with mucositis: Challenge of risk-based therapy. Clin Microbiol Infect 2001;7:47-52.
14. Gaytan-Martinez J, Mateos-Garcia E, Sanchez-Cortes E, et al. Microbiological findings in febrile neutropenia. Arch Med Res 2000;31:388-392.
15. Ena J, Dick RW, Jones RN, et al. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA 1993;269:598-602.
16. Uttley AH, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173-181.
17. Dryden M. Antibiotic resistance in enterococci at a teaching hospital. Pathology 1989;21:177-179.
18. Williamson R, Al-Obi S, Shlaes JH, et al. Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis 1989;159: 1095-1104.
19. Shlaes DM, Bouvet A, Devine C, et al. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother 1989;33:198-203.
20. McGowan JE, Jr. Gram-positive bacteria: Spread and antimicrobial resistance in university and community hospitals in the USA. J Antimicrob Chemother 1988;21:49-55.
21. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-931.
22. Veach LA, Pfaller MA, Barrett M, et al. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990;28:2064-2068.
23. Shay DK, Maloney SA, Monteclavo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
24. Edmond MB, Ober JF, Weinbaum JL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clin Inf Dis 1995;20:1126-1133.
25. Swartz MN. Hospital-acquired infections: Diseases with increasingly limited therapies. Proc Natl Acad Sci USA 1994;91:2420-2427.
26. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001;7:183-187.
27. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8:802-807.
28. Martone WJ. Spread of vancomycin-resistant enterococci: Why did it happen in the United States? Infect Control Hosp Epidemiol 1998;19:539-545.
29. Chavers LS, Moser SA, Funkhouser E, et al. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci. Microb Drug Resist 2003;9: S69-S77.
30. Henning KJ, Delencastre H, Eagan J, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: Duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-854.
31. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley and Sons, 1981.
32. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997; 50:1129-1136.
33. Mc Laren B, Shelley J. Response rates of Victorian general practitioners to a mailed survey on miscarriage: Randomized trial of a prize and two forms of introduction to the research. Aust NZ J Pub Health 2000;24:360-364.
34. Morris CJ, Cantrill JA, Weiss MC. GP survey response rate: A miscellany of influencing factors. Fam Prac 2001;18:454-456.
35. Paul M, Soares-Weiser K, Grozinsky S, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2002; CD003038.
36. Lieschke GJ, Bell D, Rawlinson W, et al. Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: An overview. Eur J Cancer Clin Oncol 1989;25: S37-S42.
37. Piguet H, Pappo M. First-line treatment of febrile episodes in leukemia in adults. Randomized, multicenter study of ceftazidime in single antibiotic therapy versus a cefotaxime-amikacin combination. Presse Med 1988;17:1954-1959.
38. Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-35.
39. Verhagen CS, de Pauw B, de Witte T, et al. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1987;31:191-196.
40. Brown AE. Management in the febrile, neutropenic patient with cancer: Therapeutic considerations. J Pediatr 1985;106:1035-1042.
41. Wade JC. Antibiotic therapy for the febrile granulocytopenic cancer patient: Combination therapy versus monotherapy. Rev Infect Dis 1989;11:81572-81581.
42. Chuang YY, Hung IJ, Yang CP, et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002;21:203-209.
43. Jandula BM, Martino R, Gurgi M, et al. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy 2001;47: 226-231.
44. Mustafa MM, Carlson L, Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001;20:362-369.
45. Kebudi R, Gorgun O, Ayan I, et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001;36: 434-441.
46. Hospital Infection Control Practices Advisory Committee (HIC-PAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-113.
47. Talcott JA, Siegel RD, Finberg R, et al. Risk Assessment in Cancer Patients with fever and neutropenia: A prospective, two-Center validation of a prediction rule. J Clin Oncol 1992;10: 316-322.
48. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996;14:919-924.
49. Klassen RJ, Gooman TR, Pham B, et al. "Low risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012-1019.
50. Klatersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrille neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
51. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996;128:847-849.
52. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-1096.